SCHEMBL244928

SCHEMBL244928

COC(=O)c1cccc(N2CCC(C)CC2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.61
KDM4E B2RXH2 4/20 0.61
KMT2A Q03164 3/20 0.61
HPGD P15428 4/20 0.60
MAPT P10636 4/20 0.60
NPC1 O15118 2/20 0.60
RAB9A P51151 1/20 0.60
GAA P10253 2/20 0.53
USP2 O75604 1/20 0.50
TP53 P04637 1/20 0.50
MEN1 O00255 2/20 0.48
CYP1A2 P05177 2/20 0.48
CYP3A4 P08684 1/20 0.48
LMNA P02545 1/20 0.48
HSD17B10 Q99714 1/20 0.48
PKM P14618 1/20 0.47
ALOX15 P16050 1/20 0.47
HTR7 P34969 1/20 0.47
CNR1 P21554 1/20 0.47
L3MBTL3 Q96JM7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10145136 0.89 GAA (0.53) ALDH1A1KDM4EKMT2AHPGDMAPT
SCHEMBL2262456 0.87 GAA (0.52) ALDH1A1KDM4EKMT2AHPGDMAPT
Hydrochloric Acid SCHEMBL3282496 0.86 GAA (0.51) ALDH1A1KDM4EKMT2AHPGDMAPT
SCHEMBL5743752 0.85 ALDH1A1 (0.66) ALDH1A1KDM4EKMT2AHPGDMAPT
SCHEMBL242325 0.85 ATM (0.57) ALDH1A1KMT2AMAPTUSP2MEN1
SCHEMBL15630696 0.84 ALDH1A1 (0.50) ALDH1A1KDM4EKMT2AHPGDMAPT
SCHEMBL4203044 0.84 ALDH1A1 (0.64) ALDH1A1KDM4EKMT2AHPGDMAPT
SCHEMBL242638 0.84 ALDH1A1 (0.69) ALDH1A1KDM4EKMT2AHPGDMAPT
SCHEMBL1490676 0.82 PLOD2 (0.60) ALDH1A1KDM4EKMT2AHPGDNPC1
SCHEMBL29040819 0.82 GAA (0.50) ALDH1A1KDM4EKMT2AHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748412-B2 Phenylalanine derivatives and their use as non-peptide GLP-1 receptor modulators ARGUSINA BIOSCIENCE INC. (KY) 2014-06-10 US disclosed
EP-2531198-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS Argusina Inc. (US) 2012-12-12 EP disclosed
US-20120004198-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS ARGUSINA INC. (US) 2012-01-05 US disclosed
WO-2011097300-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS ARGUSINA, INC. (US) 2011-08-11 WO disclosed
WO-2011094890-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS ARGUSINA INC. (US) 2011-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004198-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, GPR119 ALDH1A1 3068/4885KDM4E 1650/4885KMT2A 2731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.